The European Medicines Agency is recommending EU marketing approval for Gilead Sciences Inc.'s Epclusa (sofosbuvir/velpatasvir) and Merck & Co. Inc.'sZepatier (grazoprevir/elbasvir) after the two doublet therapies were backed by EMA's Committee for Medicinal Products for Human Use (CHMP). Europe's top drug regulator on May 27 said the two regimes allow cure of patients with long-term hepatitis C virus infection without the need for interferons, which are associated with poor tolerability and potentially serious side effects.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?